Skip to main content
Erschienen in: Clinical and Translational Oncology 1/2014

01.01.2014 | Review Article

Objective: tumor. Strategies of drug targeting at the tumor mass level

verfasst von: C. Martín Sabroso, A. I. Torres-Suárez

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Concurrent with the development of new antitumor drugs, there is intensive research to develop strategies and systems to optimize the efficacy of well-known anticancer agents. The main research lines are: (a) reduction in toxicity, (b) improvement of administration and (c) overcoming drug resistance. Drug targeting systems allow us to act on these three points. The best way to increase efficacy and reduce toxicity of an anticancer agent is targeting the drug at the level of the tumor masses and maintaining its concentration there for enough time to optimize its therapeutic action. Numerous strategies have been developed to achieve this second order targeting, based on the use of polymeric-drug conjugates, polymeric micelles, liposomes and albumin conjugates and nanoparticles, whose main features of toxicity, efficacy and administration are discussed in this review.
Literatur
1.
Zurück zum Zitat Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cáncer. Eur J Surg Oncol. 2006;32:875–6.PubMedCrossRef Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cáncer. Eur J Surg Oncol. 2006;32:875–6.PubMedCrossRef
2.
Zurück zum Zitat Martin CG. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev. 2001;53:171–6.CrossRef Martin CG. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev. 2001;53:171–6.CrossRef
3.
Zurück zum Zitat Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–4.PubMedCrossRef Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–4.PubMedCrossRef
4.
Zurück zum Zitat Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95:4607–12.PubMedCrossRef Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95:4607–12.PubMedCrossRef
5.
Zurück zum Zitat Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. J Cancer Res. 1998;89:307–14. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. J Cancer Res. 1998;89:307–14.
6.
Zurück zum Zitat Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release. 2004;99:259–69.PubMedCrossRef Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release. 2004;99:259–69.PubMedCrossRef
7.
Zurück zum Zitat Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284:109–12.PubMedCrossRef Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284:109–12.PubMedCrossRef
9.
Zurück zum Zitat Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “addictive” targets, multi-targeted drugs, new drug combinations. Drug Resist Updat. 2005;8:183–7.PubMedCrossRef Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “addictive” targets, multi-targeted drugs, new drug combinations. Drug Resist Updat. 2005;8:183–7.PubMedCrossRef
10.
Zurück zum Zitat Kawasaki ES, Player TA. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine. 2005;1:101–9.PubMed Kawasaki ES, Player TA. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine. 2005;1:101–9.PubMed
11.
Zurück zum Zitat Duncan R, Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin Pharmacokinet. 1994;27:290–6.PubMedCrossRef Duncan R, Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin Pharmacokinet. 1994;27:290–6.PubMedCrossRef
12.
Zurück zum Zitat Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61:1203–13.PubMedCrossRef Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61:1203–13.PubMedCrossRef
13.
14.
Zurück zum Zitat Singer JW. Paclitaxel poliglumex (XYOTAX™, CT-2103): a macromolecular taxane. J Control Release. 2005;109:120–6.PubMedCrossRef Singer JW. Paclitaxel poliglumex (XYOTAX™, CT-2103): a macromolecular taxane. J Control Release. 2005;109:120–6.PubMedCrossRef
15.
Zurück zum Zitat Singer JW, Baker B, De Vries P. Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology and preliminary clinical data. Adv Exp Med Biol. 2003;519:81–9.PubMedCrossRef Singer JW, Baker B, De Vries P. Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology and preliminary clinical data. Adv Exp Med Biol. 2003;519:81–9.PubMedCrossRef
16.
Zurück zum Zitat Li C, Yu DF, Newman RA. Complete regression of wellestablished tumors using a novel water-soluble poly(l-glutamic acid)–paclitaxel conjugate. Cancer Res. 1998;58:2404–9.PubMed Li C, Yu DF, Newman RA. Complete regression of wellestablished tumors using a novel water-soluble poly(l-glutamic acid)–paclitaxel conjugate. Cancer Res. 1998;58:2404–9.PubMed
17.
Zurück zum Zitat Duncan R, Cable HC, Lloyd JB, Rejmanova P, Kopecek J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci Rep. 1982;2:1041–6.PubMedCrossRef Duncan R, Cable HC, Lloyd JB, Rejmanova P, Kopecek J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci Rep. 1982;2:1041–6.PubMedCrossRef
18.
Zurück zum Zitat Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J, et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer. 1994;70:636–41.PubMedCentralPubMedCrossRef Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J, et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer. 1994;70:636–41.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev. 2010;62:203–30.PubMedCrossRef Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev. 2010;62:203–30.PubMedCrossRef
21.
Zurück zum Zitat Vicent MJ, Greco F, Paul A, Griffiths PC, Nicholson RI, Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem (Int Ed). 2005;44:4061–6.CrossRef Vicent MJ, Greco F, Paul A, Griffiths PC, Nicholson RI, Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem (Int Ed). 2005;44:4061–6.CrossRef
23.
Zurück zum Zitat Kim TY, Kim DW, Chung JY, Shin SG, Kim SC. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708–16.PubMedCrossRef Kim TY, Kim DW, Chung JY, Shin SG, Kim SC. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708–16.PubMedCrossRef
24.
Zurück zum Zitat Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17:1263–8.PubMedCrossRef Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17:1263–8.PubMedCrossRef
25.
Zurück zum Zitat Kato K, Hamaguchi T, Yasui H, Okusaka T, Ueno H. Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. J Clin Oncol. 2006;24:S83. Kato K, Hamaguchi T, Yasui H, Okusaka T, Ueno H. Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. J Clin Oncol. 2006;24:S83.
26.
Zurück zum Zitat Madaan A, Singh P, Awasthi A, Verma R, Singh AT, Jaggi M, et al. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system. NanoxelTM Clin Transl Oncol. 2013;15:26–32.CrossRef Madaan A, Singh P, Awasthi A, Verma R, Singh AT, Jaggi M, et al. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system. NanoxelTM Clin Transl Oncol. 2013;15:26–32.CrossRef
27.
Zurück zum Zitat Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8.PubMedCrossRef Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8.PubMedCrossRef
28.
Zurück zum Zitat Verma S, Dent S, Chow JW, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008;34:391–6.PubMedCrossRef Verma S, Dent S, Chow JW, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008;34:391–6.PubMedCrossRef
29.
Zurück zum Zitat Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005;96:10–8.PubMedCrossRef Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005;96:10–8.PubMedCrossRef
30.
Zurück zum Zitat Ranson M, Carmichael J, O’Byrne K. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997;15:3185–91.PubMed Ranson M, Carmichael J, O’Byrne K. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997;15:3185–91.PubMed
31.
Zurück zum Zitat Lyass O, Uziely B, Ben-Yosef R. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89(5):1037–47.PubMedCrossRef Lyass O, Uziely B, Ben-Yosef R. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89(5):1037–47.PubMedCrossRef
32.
Zurück zum Zitat Mlineritsch B, Mayer P, Rass C. Phase II study of singleagent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie. 2004;27:441–6.PubMedCrossRef Mlineritsch B, Mayer P, Rass C. Phase II study of singleagent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie. 2004;27:441–6.PubMedCrossRef
33.
Zurück zum Zitat Al-Batran SE, Bischoff J, von Minckwitz G. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer. 2006;94:1615–20.PubMedCentralPubMed Al-Batran SE, Bischoff J, von Minckwitz G. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer. 2006;94:1615–20.PubMedCentralPubMed
34.
Zurück zum Zitat Al-Batran SE, Meerpohl HG, von Minckwitz G. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70:141–6.PubMedCrossRef Al-Batran SE, Meerpohl HG, von Minckwitz G. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70:141–6.PubMedCrossRef
35.
Zurück zum Zitat Coleman RE, Biganzoli L, Canney P. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42:882–7.PubMedCrossRef Coleman RE, Biganzoli L, Canney P. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42:882–7.PubMedCrossRef
36.
Zurück zum Zitat Marty M. Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison. Breast Suppl. 2001;2:28–33.CrossRef Marty M. Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison. Breast Suppl. 2001;2:28–33.CrossRef
37.
Zurück zum Zitat Madden TD, Harrigan PR, Tai LCL. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids. 1990;53:37–46.PubMedCrossRef Madden TD, Harrigan PR, Tai LCL. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids. 1990;53:37–46.PubMedCrossRef
38.
Zurück zum Zitat Swenson CE, Perkins WR, Roberts P, Janoff AS. Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate). Breast Suppl. 2001;2:1–7.CrossRef Swenson CE, Perkins WR, Roberts P, Janoff AS. Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate). Breast Suppl. 2001;2:1–7.CrossRef
39.
Zurück zum Zitat Forssen EA. The design and development of DaunoXome® for solid tumor targeting. Adv Drug Deliv Rev. 1997;24:133–40.CrossRef Forssen EA. The design and development of DaunoXome® for solid tumor targeting. Adv Drug Deliv Rev. 1997;24:133–40.CrossRef
40.
Zurück zum Zitat Elsadek B, Kratz F. Impact of albumin on drug delivery—new applications on the horizon. J Control Release. 2012;157:4–8.PubMedCrossRef Elsadek B, Kratz F. Impact of albumin on drug delivery—new applications on the horizon. J Control Release. 2012;157:4–8.PubMedCrossRef
41.
Zurück zum Zitat Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, et al. Plasma protein (albumin) catabolism by the tumor itself—implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26:77–80.PubMedCrossRef Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, et al. Plasma protein (albumin) catabolism by the tumor itself—implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26:77–80.PubMedCrossRef
42.
Zurück zum Zitat Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z. Nanoparticle albumin—bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov. 2009;4:262–72.PubMedCrossRef Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z. Nanoparticle albumin—bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov. 2009;4:262–72.PubMedCrossRef
43.
Zurück zum Zitat Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2(2):59–64.PubMedCentralPubMed Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2(2):59–64.PubMedCentralPubMed
44.
Zurück zum Zitat Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803.PubMedCrossRef Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803.PubMedCrossRef
45.
Zurück zum Zitat Stehle G, Wunder A, Sinn H, Schrenk HH, Schütt S, Frei E, et al. Pharmacokinetics of methotrexate–albumin conjugates in tumor bearing rats. Anticancer Drugs. 1997;8:835–44.PubMedCrossRef Stehle G, Wunder A, Sinn H, Schrenk HH, Schütt S, Frei E, et al. Pharmacokinetics of methotrexate–albumin conjugates in tumor bearing rats. Anticancer Drugs. 1997;8:835–44.PubMedCrossRef
46.
Zurück zum Zitat Lim CR, Oh KH, Kim KM, Yuk SH, Lee HB, Kim CK. The enhancement of liver targetability of [3H]methotrexate-galaxtosylated serum albumin conjugate in mice. Int J Pharm. 1996;132:175–82.CrossRef Lim CR, Oh KH, Kim KM, Yuk SH, Lee HB, Kim CK. The enhancement of liver targetability of [3H]methotrexate-galaxtosylated serum albumin conjugate in mice. Int J Pharm. 1996;132:175–82.CrossRef
47.
Zurück zum Zitat Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-fusion protein in mice. Cancer Immunol Immunother. 2005;54:535–7.PubMedCrossRef Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-fusion protein in mice. Cancer Immunol Immunother. 2005;54:535–7.PubMedCrossRef
48.
Zurück zum Zitat Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem. 2000;43(7):1253–6.PubMedCrossRef Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem. 2000;43(7):1253–6.PubMedCrossRef
49.
Zurück zum Zitat Graeser R, Esser N, Unger H, Fichtner I, Zhu A. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2009;28(1):14–9.PubMedCrossRef Graeser R, Esser N, Unger H, Fichtner I, Zhu A. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2009;28(1):14–9.PubMedCrossRef
50.
Zurück zum Zitat Unger C, Haring B, Medinger M, Drevs J, Steinbild S, Kratz F, et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res. 2007;13(16):4858–66.PubMedCrossRef Unger C, Haring B, Medinger M, Drevs J, Steinbild S, Kratz F, et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res. 2007;13(16):4858–66.PubMedCrossRef
Metadaten
Titel
Objective: tumor. Strategies of drug targeting at the tumor mass level
verfasst von
C. Martín Sabroso
A. I. Torres-Suárez
Publikationsdatum
01.01.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 1/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1075-4

Weitere Artikel der Ausgabe 1/2014

Clinical and Translational Oncology 1/2014 Zur Ausgabe

Acknowledgement to Referees

Acknowledgement to Referees 2013

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.